Clinical trial
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
NCT00868959 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00868959 |
|---|---|
| Title | Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression |
| Official title | A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Depression |
| Intervention type | Drug |
| Interventions | lurasidone |
| Enrollment | 817 |
| Start date | Apr 1, 2009 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | Mar 25, 2009 |
| Last update posted | Apr 14, 2016 |
| Countries | Canada, Colombia, Czechia, France, India, Japan, Lithuania, Peru, Poland, Romania, Russia, Slovakia and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: